Comparative Pharmacology
Head-to-head clinical analysis: ALTACE versus CAPOZIDE 50 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTACE versus CAPOZIDE 50 25.
ALTACE vs CAPOZIDE 50/25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin-converting enzyme inhibitor; inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion.
Captopril is an angiotensin-converting enzyme (ACE) inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
2.5-5 mg orally once daily initially, titrated to 10-20 mg once daily; maximum 20 mg/day
One tablet (captopril 50 mg / hydrochlorothiazide 25 mg) orally once daily; may increase to two tablets daily if needed.
None Documented
None Documented
Ramiprilat: 13–17 hours (prolonged in renal impairment, up to 50 hours in severe renal insufficiency; multiple doses: 45–60 hours effective half-life due to tissue binding)
Captopril: ~2 hours (increased in renal impairment). Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment). Clinical context: dosing interval typically 12-24 hours.
Renal: 60% (30% as ramiprilat, 30% as metabolites); Fecal: 40% (unabsorbed drug and biliary metabolites)
Captopril: 95% renal (primarily unchanged). Hydrochlorothiazide: 95% renal (unchanged).
Category C
Category C
ACE Inhibitor
ACE Inhibitor/Diuretic Combination